Zobrazeno 1 - 10
of 604
pro vyhledávání: '"David P Lane"'
Autor:
Marcus J G W Ladds, Andrés Pastor-Fernández, Gergana Popova, Ingeborg M M van Leeuwen, Kai Er Eng, Catherine J Drummond, Lars Johansson, Richard Svensson, Nicholas J Westwood, Anna R McCarthy, Fredrik Tholander, Mihaela Popa, David P Lane, Emmet McCormack, Gerald M McInerney, Ravi Bhatia, Sonia Laín
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195956 (2018)
Tenovin-6 is the most studied member of a family of small molecules with antitumour activity in vivo. Previously, it has been determined that part of the effects of tenovin-6 associate with its ability to inhibit SirT1 and activate p53. However, teno
Externí odkaz:
https://doaj.org/article/0fd1ac03689f431cac754c84ca4df77d
Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids.
Autor:
Sharon Min Qi Chee, Jantana Wongsantichon, Jiawei Siau, Dawn Thean, Fernando Ferrer, Robert C Robinson, David P Lane, Christopher J Brown, Farid J Ghadessy
Publikováno v:
PLoS ONE, Vol 12, Iss 12, p e0189379 (2017)
As primary p53 antagonists, Mdm2 and the closely related Mdm4 are relevant cancer therapeutic targets. We have previously described a series of cell-permeable stapled peptides that bind to Mdm2 with high affinity, resulting in activation of the p53 t
Externí odkaz:
https://doaj.org/article/fdc2d7bd24ff4e5e8f8b236a8417e65d
Autor:
Sharon Min Qi Chee, Jantana Wongsantichon, Quah Soo Tng, Robert Robinson, Thomas L Joseph, Chandra Verma, David P Lane, Christopher J Brown, Farid J Ghadessy
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e104914 (2014)
As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic target. Small molecules such as Nutlin have been developed to antagonise Mdm2, resulting in p53-dependent death of tumour cells. We have recently described a mu
Externí odkaz:
https://doaj.org/article/75e1615ecfa7434bab2588d9679c1fc7
Autor:
Katrine Ingelshed, Marit M. Melssen, Pavitra Kannan, Arun Chandramohan, Anthony W. Partridge, Long Jiang, Fredrik Wermeling, David P. Lane, Marika Nestor, Diana Spiegelberg
Publikováno v:
iScience, Vol 27, Iss 6, Pp 109862- (2024)
Summary: Immunotherapy has revolutionized cancer treatment but its efficacy depends on a robust immune response in the tumor. Silencing of the tumor suppressor p53 is common in tumors and can affect the recruitment and activation of different immune
Externí odkaz:
https://doaj.org/article/a6f5c387d3ed4365a35bb503c9592eba
Autor:
Dilraj Lama, Thibault Vosselman, Cagla Sahin, Judit Liaño-Pons, Carmine P. Cerrato, Lennart Nilsson, Kaare Teilum, David P. Lane, Michael Landreh, Marie Arsenian Henriksson
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract The c-MYC oncogene is activated in over 70% of all human cancers. The intrinsic disorder of the c-MYC transcription factor facilitates molecular interactions that regulate numerous biological pathways, but severely limits efforts to target i
Externí odkaz:
https://doaj.org/article/dc5827f1d64e4af7bed720320a85059d
Autor:
Arun Chandramohan, Hubert Josien, Tsz Ying Yuen, Ruchia Duggal, Diana Spiegelberg, Lin Yan, Yu-Chi Angela Juang, Lan Ge, Pietro G. Aronica, Hung Yi Kristal Kaan, Yee Hwee Lim, Andrea Peier, Brad Sherborne, Jerome Hochman, Songnian Lin, Kaustav Biswas, Marika Nestor, Chandra S. Verma, David P. Lane, Tomi K. Sawyer, Robert Garbaccio, Brian Henry, Srinivasaraghavan Kannan, Christopher J. Brown, Charles W. Johannes, Anthony W. Partridge
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Although stapled α-helical peptides can address challenging targets, their advancement is impeded by poor understandings for making them cell permeable while avoiding off-target toxicities. By synthesizing >350 molecules, we present workflo
Externí odkaz:
https://doaj.org/article/244b34e3aef44b508696598d0927724f
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e80221 (2013)
The transcription factor p53 regulates cellular integrity in response to stress. p53 is mutated in more than half of cancerous cells, with a majority of the mutations localized to the DNA binding domain (DBD). In order to map the structural and dynam
Externí odkaz:
https://doaj.org/article/337402e244814aa5ab71c3ab5ad436b4
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e47235 (2012)
Eukaryotic initiation factor (eIF)4E is over-expressed in many types of cancer such as breast, head and neck, and lung. A consequence of increased levels of eIF4E is the preferential translation of pro-tumorigenic proteins (e.g. c-Myc and vascular en
Externí odkaz:
https://doaj.org/article/55da2c89814e4f45acde4561acea2d16
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e43985 (2012)
Atomistic simulations of a set of stapled alpha helical peptides derived from the BH3 helix of MCL-1 (Stewart et al. (2010) Nat Chem Biol 6: 595-601) complexed to a fragment (residues 172-320) of MCL-1 revealed that the highest affinity is achieved w
Externí odkaz:
https://doaj.org/article/fffe6b2a38e8478b87a25c55fafbf269
Autor:
Teresa Lai Fong Ho, May Yin Lee, Hui Chin Goh, Germaine Yi Ning Ng, Jane Jia Hui Lee, Srinivasaraghavan Kannan, Yan Ting Lim, Tianyun Zhao, Edwin Kok Hao Lim, Cheryl Zi Jin Phua, Yi Fei Lee, Rebecca Yi Xuan Lim, Perry Jun Hao Ng, Ju Yuan, Dedrick Kok Hong Chan, Bettina Lieske, Choon Seng Chong, Kuok Chung Lee, Jeffrey Lum, Wai Kit Cheong, Khay Guan Yeoh, Ker Kan Tan, Radoslaw M. Sobota, Chandra S. Verma, David P. Lane, Wai Leong Tam, Ashok R. Venkitaraman
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)
Here the authors identify distinct mechanisms by which domain-specific p53 mutations activate cancer cell growth via the epidermal growth factor receptor (EGFR). These mechanisms affect sensitivity to EGFR inhibitors, opening avenues for targeted the
Externí odkaz:
https://doaj.org/article/887b89f317fb487d8e09152d6d299ac4